This continuing feature will update readers on recent developments in cardiovascular pharmacotherapy. Cardiovascular disease remains the number one killer in the US, and more clinical outcome trials have been conducted in cardiology than in any other field of medicine. Given this rapidly expanding knowledge base, pharmacists can have a significant impact on prevention and treatment — if they keep current with developments in drug therapy. Address comments to Patricia A. Howard, PharmD, Professor and Vice Chair, Pharmacy Practice, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS, 66160–7231. E-mail: phoward@kumc.edu.
Get full access to this article
View all access options for this article.
References
1.
The seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure: The JNC 7 report. JAMA.2003; 289: 2560–72.
2.
The sixth report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Arch Intern Med.1997;157: 2413–46. (Erratum, Arch Intern Med. 1998;158:573.)
3.
VasanR.S., LarsonM.G., LeipE.P.Assessment of frequency or progression to hypertension in nonhypertensive participants in the Framingham Heart Study. Lancet.2001; 358: 1682–6.
4.
LewingtonS., ClarkeR., QizilbashN.Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet.2001; 360: 1903–13.
5.
NealB., MacMahonS., ChapmanN.Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs. Lancet.2000; 356: 1955–64.
6.
SacksF.M., SvetkeyL.P., VollmerW.M.For the DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med.2001; 344: 3–10.
7.
MooreT.J., VollmerW.M., AppelL.J.Effect of dietary patterns on ambulatory blood pressure: Results from the Dietary Approaches to Stop Hypertension (DASH) Trial. DASH Collaborative Research Group. Hypertension.1999; 34: 472–7.
8.
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA.2002; 288: 2981–97.
9.
PsatyB.M., LumleyT., FurbergC.D.Health outcomes associated with various antihypertensive therapies used as first-line agents: A network meta-analysis. JAMA.2003; 289: 2534–44.
10.
WingL.M., ReidC.M., RyanP.for the Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med.2003; 348: 583–92.
11.
The GISEN (Gruppo Italiano di Studi Epidemiologici in Nefrologia) Group.Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet.1997; 349: 1857–63.
12.
WrightJ.T.Jr., ArgodoaL., ContrerasG.Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. Arch Intern Med.2002; 162: 1636–43.
13.
PROGRESS Collaborative Group.Randomised trial of a perindopril-based blood pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet.2001; 358: 1033–41.
14.
The Heart Outcomes Prevention Evaluation Study Investigators.Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med.2000; 342: 145–53.
15.
DahlofB., DevereuxR.B., KjeldsenS.E.Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE). Lancet.2002; 359: 995–1003.
16.
BrennerB.M., CooperM.E., deZeeuwD.Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephorpathy. N Engl J Med.2001; 345: 861–9.
17.
LewisE.J., JunsickerL.G., ClarkeW.R.Renoprotective effects of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med.2001; 345: 851–60.
18.
Guidelines Committee.2003 European Society of Hypertension-European Society of Cardiology. Guidelines for the management of arterial hypertension. J Hypertens.2003; 21: 1011–53.
19.
American Heart Association.Heart Disease and Stroke Statistics – 2003 Update.Dallas, TX: AHA;2002.
20.
HajjarI., KotchenT.A.Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA.2003; 290: 199–206.
21.
FlegalK.M., CarrollM.D., OgdenC.L.Pevalence and trends in obesity among US adults, 1999–2000. JAMA.2002; 288: 1723–7.
22.
National Cholesterol Education Program.Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation.2002; 106: 3143–421.
